Ginkgo Bioworks Holdings, Inc.
DNANYSE
$7.91
↓ -4.6%Jul 17 close · end-of-day
Price
1Y↓ -17.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$151.4M
Net Income (TTM)
—
Free Cash Flow (TTM)
-$168.2M
Gross Margin
—
Operating Margin
-201.9%
Net Margin
—
ROE
—
ROIC
-80.7%
Debt / Equity
—
Net Cash
$143.9M
Return 1Y
-18.9%
Company profile
Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
- CEO
- Jason Kelly
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 640
- Headquarters
- Massachusetts
- Website
- ginkgobioworks.com
Management & directors
- Coen Steven P.See remarks
- Shetty Reshma P.See remarks
- Kelly Jason RSee remarks
Roles derived from SEC Form 4 filings.
Earnings
DNA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$19.5M↓ -49.1%
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $76.7M | $313.8M | $477.7M | $251.5M | $227.0M | $170.2M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$137.0M | -$1.8B | -$2.2B | -$864.4M | -$559.8M | -$315.3M |
| Net income | -$126.6M | -$1.8M | -$2.1M | -$893,000.00 | -$547,000.00 | -$313,000.00 |
| Diluted EPS | -$0.10 | -$1.39 | -$50.20 | -$18.37 | -$10.54 | -$5.64 |
| Operating cash flow | -$135.8M | -$253.8M | -$252.2M | -$295.5M | -$319.6M | -$171.1M |
| Free cash flow | -$193.7M | -$310.3M | -$304.5M | -$336.3M | -$382.1M | -$178.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -178.8% | -582.6% | -462.4% | -343.8% | -246.5% | -185.3% |
| Net margin | -165.2% | -0.6% | -0.4% | -0.4% | -0.2% | -0.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $56.2M | $89.0M | $43.8M | $38.2M | $49.6M | $38.8M | $43.5M | $19.5M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$222.9M | -$55.2M | -$103.6M | -$81.0M | -$65.5M | -$90.0M | -$78.7M | -$71.4M |
| Net income | -$217.2M | -$56.4M | — | -$91.0M | — | -$80.8M | — | -$82.6M |
| Diluted EPS | -$4.23 | -$1.08 | -$1.91 | -$1.68 | -$1.10 | -$1.45 | -$1.41 | — |
| Operating cash flow | -$84.4M | -$103.5M | -$42.4M | -$51.5M | -$40.3M | -$31.6M | -$47.7M | -$46.7M |
| Free cash flow | -$111.4M | -$118.6M | -$56.1M | -$59.1M | -$40.3M | -$31.6M | -$47.7M | -$48.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -396.7% | -62.0% | -236.3% | -211.8% | -132.1% | -231.8% | -181.1% | -366.5% |
| Net margin | -386.4% | -63.3% | — | -237.9% | — | -207.9% | — | -424.1% |
Company news
May 22, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-22 | Coen Steven P.· See remarks | Sale | 307 | $8.33 | $2,558.54 | filing |
| 2026-05-21 | Coen Steven P.· See remarks | Option exercise | 587 | — | — | filing |
| 2026-05-21 | Coen Steven P.· See remarks | Option exercise | 156 | — | — | filing |
| 2026-04-17 | Coen Steven P.· See remarks | Sale | 324 | $7.95 | $2,576.45 | filing |
| 2026-04-16 | Coen Steven P.· See remarks | Option exercise | 156 | — | — | filing |
| 2026-04-16 | Coen Steven P.· See remarks | Option exercise | 587 | — | — | filing |
| 2026-04-13 | Coen Steven P.· See remarks | Sale | 33,171 | $6.41 | $212,758.79 | filing |
| 2026-04-10 | Canton Barry | Sale | 124,727 | $6.43 | $802,493.52 | filing |
| 2026-04-10 | Shetty Reshma P.· See remarks | Sale | 124,727 | $6.43 | $802,493.52 | filing |
| 2026-04-10 | Coen Steven P.· See remarks | Option exercise | 28,368 | — | — | filing |
| 2026-04-10 | Coen Steven P.· See remarks | Option exercise | 45,553 | — | — | filing |
| 2026-04-09 | Kelly Jason R· See remarks | Sale | 109,767 | $6.40 | $702,179.50 | filing |
| 2026-04-09 | Shetty Reshma P.· See remarks | Sale | 13,116 | $6.40 | $83,903.05 | filing |
| 2026-04-09 | Canton Barry | Sale | 13,116 | $6.40 | $83,903.05 | filing |
| 2026-04-09 | Shetty Reshma P.· See remarks | Option exercise | 251,786 | — | — | filing |
| 2026-04-09 | Canton Barry | Option exercise | 251,786 | — | — | filing |
| 2026-04-08 | Kelly Jason R· See remarks | Sale | 97,015 | $6.93 | $672,313.95 | filing |
| 2026-04-08 | Canton Barry | Sale | 13,155 | $6.93 | $91,164.15 | filing |
| 2026-04-08 | Shetty Reshma P.· See remarks | Sale | 13,155 | $6.93 | $91,164.15 | filing |
| 2026-04-08 | Kelly Jason R· See remarks | Option exercise | 212,949 | — | — | filing |
| 2026-04-08 | Shetty Reshma P.· See remarks | Option exercise | 27,738 | — | — | filing |
| 2026-04-08 | Canton Barry | Option exercise | 27,738 | — | — | filing |
| 2026-04-07 | Shetty Reshma P.· See remarks | Option exercise | 27,738 | — | — | filing |
| 2026-04-07 | Canton Barry | Option exercise | 27,738 | — | — | filing |
| 2026-04-07 | Kelly Jason R· See remarks | Option exercise | 212,949 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.